New Report Explains How Big Data and the Therapeutic Pipeline Will be Life Changing for 250,000 People Living with Neuromuscular Disease

To learn more about this report, please read our press release.

Neuromuscular diseases encompass a broad group of disorders that are individually rare but collectively impact an estimated 250,000 patients in the United States, breaking the rare disease threshold of 200,000 individuals. Currently, treatment options for these diseases are limited. But the financial impact is staggering; costs related to neuromuscular diseases exceed $46 billion dollars annually.

A new report, “Understanding Neuromuscular Disease Care,” funded by the Muscular Dystrophy Association (MDA) and released by the IQVIA Institute for Data Science, shows that advancements in genetic testing and precision medicine will radically alter the course of neuromuscular disease within the next decade. The report illuminates the role that big data technologies will play in revolutionizing the importance of newborn screening, early genetic testing, intervention and treatment as pathways to accelerating new therapies.

As the umbrella organization for more than 40 neuromuscular diseases, and with the advent of our comprehensive data hub, MOVR, MDA is driving the advancement of research, new technologies and care strategies to galvanize both the industry and research arenas to pioneer better care and more cures. MDA has high expectations for advancing patient care and bringing disease-modifying therapies across neuromuscular diseases to patients and their families.

Donate today to help us in our mission to transform the lives of people with muscular dystrophy, ALS and other neuromuscular diseases.